Teligent: FDA Approves Triamcinolone Acetonide Ointment, Launch Planned For Q2

(RTTNews) - Teligent, Inc. (TLGT), a specialty generic pharmaceutical company, announced Monday that it has received approval of its abbreviated new drug application or ANDA from the U.S. Food and Drug Administration or FDA of Triamcinolone Acetonide Ointment USP, 0.1%.

The Company said it will launch Triamcinolone Acetonide Ointment USP, 0.1% in 15 gram and 80 gram tubes and a one pound jar.

Teligent originally submitted this ANDA to the FDA in January 2013. This is Teligent's fifth approval from its internally developed pipeline of topical generic pharmaceutical products.

Based on IMS Health data from March 2016, the total addressable market for Triamcinolone Acetonide Ointment USP, 0.1% is approximately $24 million.

Jason Grenfell-Gardner, President and CEO, said, "This is our fourth prescription topical ANDA approved by the FDA so far this year, including the recent approval of a partnered submission. Our commercialization team expects to launch Triamcinolone Acetonide Ointment USP, 0.1% in the second quarter of 2016."